U.S. Online Retail and Ecommerce Stock News

Q1 2026 earnings snapshot Cummins (CMI) has kicked off 2026 with Q1 results that follow a year where trailing 12 month revenue sat at US$33.7b and Basic EPS was US$20.62, alongside a net income of US$2.8b. Over the last six reported quarters, revenue has ranged from US$8.2b to US$8.6b per quarter while Basic EPS moved between US$3.04 and US$6.46, giving investors a clear view of how earnings track against a relatively tight revenue band. With margins that recently eased from prior levels, the...

Hess Midstream (HESM) opened 2026 earnings season with Q1 results that sit against a backdrop of 2025 revenue between US$382 million and US$420.9 million per quarter and basic EPS ranging from US$0.65 to US$0.75, with trailing 12 month revenue at US$1.62 billion and basic EPS of US$2.87. Over the last year, revenue has moved from US$378.5 million in Q3 2024 to US$404.2 million in Q4 2025, while basic EPS has shifted from US$0.63 to US$0.72, giving investors a clear view of how both the top...

Boise Cascade (BCC) has just reported its Q1 2026 results against a backdrop where recent quarters showed Q4 2025 revenue of about US$1.5b and basic EPS of roughly US$0.24, alongside trailing 12 month revenue of about US$6.4b and basic EPS of US$3.54. Over the past six reported quarters, revenue has ranged from roughly US$1.5b to US$1.7b while quarterly EPS has moved between about US$0.24 and US$2.34. This sets up the latest update as a check in on how margins are holding up across the...

AvalonBay Communities, Inc. recently reported past first-quarter 2026 results showing higher revenue of US$770.28 million and net income of US$325.73 million, issued new EPS guidance for the second quarter and full year 2026, completed US$500 million in share repurchases across two authorizations, and filed a US$40 million ESOP-related common stock shelf registration. This combination of stronger earnings, fresh guidance, and active capital management highlights how AvalonBay is balancing...

If you are wondering whether ICON's current share price reflects its underlying value, the recent moves in the stock give you a timely reason to take a closer look. The stock recently closed at US$121.32, with returns of 18.4% over 7 days and 6.2% over 30 days, set against a year-to-date return of a 35.7% decline and a 10.2% decline over the past year. These price moves have come as ICON continues to attract attention in the contract research and life sciences outsourcing space, where...

BWX Technologies (BWXT) has just wrapped up Q1 2026 with investors looking closely at how the recent revenue and EPS trajectory sets the tone for the new year, particularly after trailing 12 month net income of US$328.9 million and basic EPS of US$3.59 against a current share price of US$206.15. Over the last six reported quarters, revenue has moved from US$671.9 million in Q3 2024 to US$885.8 million in Q4 2025, while quarterly basic EPS has ranged from US$0.76 to US$1.02, giving investors a...

Cathay General Bancorp reported first-quarter 2026 results, with net interest income rising to US$194.17 million and net income reaching US$86.89 million, alongside higher earnings per share versus a year earlier. On the same day, the company disclosed it had completed a US$150.00 million buyback program and announced a new share repurchase authorization of up to US$150.00 million, underscoring continued capital returns alongside earnings growth. With stronger quarterly earnings and a fresh...

Why MKS Stock Is On Investors’ Radar MKS (MKSI) has been drawing attention after a strong run over the past year, with the stock’s recent price of $287.65 sitting against a backdrop of multi segment semiconductor exposure. See our latest analysis for MKS. The recent pullback in the share price over the last day contrasts with a strong run, with a 30 day share price return of 22.6% and a 1 year total shareholder return of very close to 300%. This suggests that momentum has been building rather...

If you are wondering whether Catalyst Pharmaceuticals' recent share price puts it at a bargain or a stretch, the following sections break that question down into clear valuation checks. The stock last closed at US$30.86, with returns of 4.8% over the past week, 25.0% over the past month, 33.3% year to date and 33.8% over the past year, which raises questions about how that performance lines up with underlying value. Recent headlines around Catalyst Pharmaceuticals have focused on its...

Grab Holdings (NasdaqGS:GRAB) has agreed to acquire Delivery Hero’s foodpanda business in Taiwan, marking its first major move beyond Southeast Asia. The deal extends Grab’s delivery footprint into a new market where it has not previously operated. Indonesia has introduced a new regulatory cap on ride hailing commissions, cutting the maximum rate from 20% to 8% and adding new social protections for drivers. These regulatory changes directly affect Grab’s largest regional market and could...

If you are wondering whether BlackSky Technology's current share price reflects its true worth, the recent performance gives plenty to think about. The stock last closed at US$35.96, with returns of 15.2% over 7 days, 16.7% over 30 days, 72.7% year to date, 321.1% over 1 year and 284.2% over 3 years, while the 5 year return sits at a 54.6% decline. Recent price action has drawn attention to BlackSky Technology, with investors focusing on how current expectations align with the stock's past...

BioMarin Pharmaceutical (BMRN) opened 2026 with Q1 results that build on a run of quarterly revenue between US$745.1 million and US$874.6 million over 2025, while EPS has swung from a profit of US$1.25 in Q2 2025 to a loss of US$0.24 in Q4 2025 as one off items fed into the reported figures. Over the last six reported quarters, revenue has ranged from about US$745.1 million to US$874.6 million and trailing 12 month EPS has moved between US$1.70 and US$3.44. This gives you a clear view of how...

Axsome Therapeutics (AXSM) Q1 2026 earnings snapshot Axsome Therapeutics (AXSM) has opened 2026 with Q1 revenue of US$191.2 million and a basic EPS loss of US$1.26, alongside a net loss of US$64.5 million, setting a clear benchmark for how the rest of the year might look. The company has seen revenue progress from US$118.8 million in Q4 2024 to US$191.2 million in Q1 2026, while trailing twelve month EPS has moved from a loss of US$5.99 to a loss of US$3.74 as revenue reached US$708.2 million...

Market snapshot and recent returns Solventum (SOLV) has drawn fresh attention after a period of mixed share performance, with a 2.4% move over the past day and a month gain of 8.6% contrasting with a 9.7% decline over the past 3 months. At a last close of $69.04, the company has a value score of 5 and a market cap of about $11.7b. This has invited closer scrutiny of how its healthcare operations and recent results line up with current pricing. See our latest analysis for Solventum. For...

Ameresco Q1 2026 earnings in focus Ameresco (AMRC) has come into Q1 2026 with recent quarterly figures that show Q4 2025 revenue at US$581.0 million and basic EPS of US$0.35, alongside trailing twelve month revenue of about US$1.9 billion and basic EPS of US$0.84. The company has seen quarterly revenue move from US$500.9 million in Q3 2024 to US$581.0 million in Q4 2025, while basic EPS over those reported quarters ranged from US$0.24 to US$0.71. This sets up the latest update against a...

In recent days, Tyra Biosciences reported interim Phase 1/2 data for its lead candidate TYRA-300 in metastatic urothelial carcinoma, showing an objective response rate alongside a favorable safety profile. At the same time, the company advanced its bladder cancer pipeline through a new SURF302 trial partnership with the University of Kansas Medical Center, highlighting external confidence in its FGFR3-focused approach. Next, we will examine how TYRA-300’s interim efficacy signal shapes...

Wondering if BeOne Medicines at around US$297.49 is still offering value after a strong run? This article focuses squarely on what that price might really represent. The stock has returned 23.1% over the past year. The shorter term picture shows a 0.2% slip over 7 days, 4.3% over 30 days and 4.4% year to date. Recent news around BeOne Medicines has kept attention on the stock, with investors weighing how company developments align with its current share price. These headlines help frame...

If you are asking whether Fiserv at around US$57.28 is a bargain or a value trap, you will want to understand what the current valuation signals are really saying. The stock has seen a 7% decline over the last 7 days, a 2% gain over the last 30 days, a 12.7% decline year to date, and a 69% decline over the last year, which can change how the market prices its potential and its risks. Recent commentary around Fiserv has focused on its position within diversified financial services and how it...

Wondering if Match Group at around US$37.65 is offering value or just noise? This article breaks down what the current price might be implying about the stock. The stock has returned 1.7% over the last 7 days, 19.8% over the last 30 days, 18.6% year to date and 28.7% over the last year, while the 5 year return sits at a 73.4% decline. These moves come as investors continue to reassess online dating platforms and subscription based business models. Match Group is often in focus during broader...

Adeia (ADEA) sets the tone with Q1 2026 results Adeia (ADEA) opened Q1 2026 with trailing 12 month revenue of US$443.4 million and basic EPS of US$1.02, following a recent quarter where it booked US$182.6 million in revenue and basic EPS of US$0.68. Over the past year, revenue has moved from US$376.0 million to US$443.4 million on a trailing basis, while trailing basic EPS shifted from US$0.59 to US$1.02, giving investors a clearer view of how topline and per share earnings have tracked ahead...

Wondering whether Nucor at around US$232 per share is offering value or stretching expectations? This article focuses squarely on what the current price may imply. The stock has returned 3.1% over the last 7 days, 34.6% over the last 30 days, 37.0% year to date and 101.6% over the last year, which naturally raises questions about how much future potential is already reflected in the price. Recent coverage of steel producers and materials suppliers has highlighted how investor attention often...

Black Rifle Coffee (BRCC) has just put fresh numbers on the table for Q1 2026, with recent quarters showing revenue of US$112.7 million in Q4 2025 and a basic EPS loss of US$0.03 alongside a net loss of US$3.2 million. Over the past six reported quarters, revenue has ranged from US$89.9 million to US$112.7 million, while basic EPS has stayed in loss-making territory between about US$0.00 and US$0.07 per share. This puts the focus for investors squarely on how margins are trending from...

Donnelley Financial Solutions (DFIN) opened 2026 earnings season with Q1 numbers that come on the heels of Q4 2025 revenue of $172.5 million, basic EPS of $0.24 and net income of $6.2 million. These results are set against a trailing net margin that has moved from 11.8% a year ago to 4.2% after a $92.8 million one-off loss. Over recent quarters, the company has reported revenue ranging between $156.3 million and $218.1 million, while basic EPS has moved from a loss of $1.49 in Q3 2025 to...

Q1 2026 earnings snapshot for CPI Card Group (PMTS) CPI Card Group (PMTS) has opened Q1 2026 earnings season with investors focused on how its recent revenue base of about US$543.5 million and trailing EPS of roughly US$1.32 over the last reported twelve months frame the story after a period of softer profitability. Over the past year, the company has seen revenue progress from US$480.6 million in 2024 Q4 to US$543.5 million in 2025 Q4, while quarterly EPS has moved between US$0.05 and...